The role of the atherogenic index of plasma in response to once-daily tadalafil in men with erectile dysfunction

ROC analysis yielded an AUC of 0.650 (95% CI 0.540–0.760, <i>p </i>= 0.008), with an optimal cutoff of 0.130.</p> <p>Higher baseline AIP was independently associated with nonresponse to once-daily tadalafil in men with ED, suggesting AIP may offer additional prognostic information, though further validation is needed.</p> <p></p><p>The atherogenic index of plasma (AIP), derived from routine lipid measurements, may provide simple pretreatment information in men with erectile dysfunction initiating once-daily tadalafil.</p><p>Higher baseline AIP levels were associated with a lower likelihood of clinically meaningful response to tadalafil in this cohort.</p><p>Diabetes mellitus was also independently associated with nonresponse, supporting the importance of broader metabolic assessment in erectile dysfunction management.</p><p>Given its modest discriminatory ability, AIP should be considered a potential adjunctive marker rather than a stand-alone clinical decision tool.</p><p></p> <p>The atherogenic index of plasma (AIP), derived from routine lipid measurements, may provide simple pretreatment information in men with erectile dysfunction initiating once-daily tadalafil.</p> <p>Higher baseline AIP levels were associated with a lower likelihood of clinically meaningful response to tadalafil in this cohort.</p> <p>Diabetes mellitus was also independently associated with nonresponse, supporting the importance of broader metabolic assessment in erectile dysfunction management.</p> <p>Given its modest discriminatory ability, AIP should be considered a potential adjunctive marker rather than a stand-alone clinical decision tool.</p>